Role of nuclear receptors in hepatitis B and C infections

被引:2
作者
Andre, Patrice [1 ,2 ]
Ramiere, Christophe [1 ]
Scholtes, Caroline [1 ,2 ]
Curtil, Claire [1 ,2 ]
Lotteau, Vincent [1 ]
机构
[1] Univ Lyon 1, INSERM, U851, IFR Biosci Lyon Gerland 128, F-69007 Lyon, France
[2] Hosp Civils Lyon, Virol Lab, F-69004 Lyon, France
关键词
VIRUS CORE PROTEIN; FETOPROTEIN TRANSCRIPTION FACTOR; INSULIN-RESISTANCE; DIABETES-MELLITUS; OXIDATIVE STRESS; CCCDNA FUNCTION; LIPID DROPLET; LOW-DENSITY; BILE-ACIDS; REPLICATION;
D O I
10.1016/j.clinre.2011.01.001
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nuclear receptors are key regulators of many cellular functions including energy supply by the direct control of the expression of target genes. They constitute a super-family of transcription factors activated by ligands, hormones or metabolites, and therefore, sensible to host metabolic stimuli. Viral replication and production requires energy and elementary building blocks from the infected cells. Hepatitis B and C virus replication is modulated in part by liver nuclear receptors that regulate the glucose and lipid metabolism. However, nuclear receptors control the two viruses' replication by different mechanisms. The expression of hepatitis B virus genes is directly under the control of nuclear receptors, which bind to the viral genome regulatory regions. Viral replication and production may, therefore, be optimal when cells receive the correct metabolic signals. Hepatitis C virus replication and production depend to a large extent on lipidogenesis and lipoprotein secretion. The role of nuclear receptors in controlling hepatitis C replication may be to turn on the cellular mode that would provide the appropriate metabolic environment for viral replication. (C) 2011 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:169 / 175
页数:7
相关论文
共 61 条
  • [1] EVIDENCE FOR A LINK BETWEEN HEPATITIS-C VIRUS-INFECTION AND DIABETES-MELLITUS IN A CIRRHOTIC POPULATION
    ALLISON, MED
    WREGHITT, T
    PALMER, CR
    ALEXANDER, GJM
    [J]. JOURNAL OF HEPATOLOGY, 1994, 21 (06) : 1135 - 1139
  • [2] Characterization of low- and very-low-density hepatitis C virus RNA-containing particles
    André, P
    Komurian-Pradel, F
    Deforges, S
    Perret, M
    Berland, JL
    Sodoyer, M
    Pol, S
    Bréchot, C
    Paranhos-Baccalà, G
    Lotteau, V
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (14) : 6919 - 6928
  • [3] Hepatitis C virus particles and lipoprotein metabolism
    André, P
    Perlemuter, G
    Budkowska, A
    Bréchot, C
    Lotteau, V
    [J]. SEMINARS IN LIVER DISEASE, 2005, 25 (01) : 93 - 104
  • [4] Andre Patrice, 2008, J Hepatol, V49, P153, DOI 10.1016/j.jhep.2008.04.005
  • [5] Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function
    Belloni, Laura
    Pollicino, Teresa
    De Nicola, Francesca
    Guerrieri, Francesca
    Raffa, Giuseppina
    Fanciulli, Maurizio
    Raimondo, Giovanni
    Levrero, Massimo
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (47) : 19975 - 19979
  • [6] Gene Expression Profiling Indicates the Roles of Host Oxidative Stress, Apoptosis, Lipid Metabolism, and Intracellular Transport Genes in the Replication of Hepatitis C Virus
    Blackham, Samantha
    Baillie, Andrew
    Al-Hababi, Fadel
    Remlinger, Katja
    You, Shihyun
    Hamatake, Robert
    McGarvey, Michael J.
    [J]. JOURNAL OF VIROLOGY, 2010, 84 (10) : 5404 - 5414
  • [7] Block Timothy M, 2007, Clin Liver Dis, V11, P685, DOI 10.1016/j.cld.2007.08.002
  • [8] Structural organization of the hepatitis B virus minichromosome
    Bock, CT
    Schwinn, S
    Locarnini, S
    Fyfe, J
    Manns, MP
    Trautwein, C
    Zentgraf, H
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2001, 307 (01) : 183 - 196
  • [9] Chromatin Remodeling and Nuclear Receptor Signaling
    Buranapramest, Manop
    Chakravarti, Debabrata
    [J]. REGULATORY MECHANISMS IN TRANSCRIPTIONAL SIGNALING, 2009, 87 : 193 - 234
  • [10] Farnesoid X receptor modulators: a patent review
    Crawley, Matthew Lantz
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (08) : 1047 - 1057